In this episode of Data in Biotech, Ross Katz chats with Mitra Mosharraf, Chief Scientific Officer at HTD Biosystems, about how AI and machine learning are revolutionizing nanomedicine. They explore the use of AI in drug discovery, formulation, manufacturing, and clinical development, highlighting how data-driven strategies are improving safety, reducing costs, and enabling more personalized therapies in the biotech space.

What you'll learn in this episode:

>> How AI and ML reduce costs and increase success rates in nanomedicine development.

>> Key challenges in nano drug delivery and how machine learning helps overcome them.

>> How HTD Biosystems' iFormulate platform speeds up formulation with predictive modeling.

>> How wearables and real-time data are reshaping clinical trial design.

>> The future of personalized and automated drug delivery systems.

Meet our guest

Mitra Mosharraf is the Chief Scientific Officer at HTD Biosystems and co-founder of Engimata Inc. With 20+ years of experience, she leads innovation in biologics, nanomedicine, and lipid-based delivery systems. Mitra is a recognized thought leader in pharmaceutical sciences.

About the host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

Sponsor: CorrDyn, a data consultancy
Connect with Mitra Mosharraf on LinkedIn

Connect with Us:

Follow the podcast for more insightful discussions on the latest in biotech and data science.
Subscribe and leave a review if you enjoyed this episode!
Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.